Most peptide oral sprays are sold on an absorption claim that nobody has measured. The mouth is not the digestive tract, but it is not an open door either: saliva clears a liquid dose, the lining of the cheek is a poor surface for peptide uptake, and the approved peptides that do cross a mucosal barrier needed purpose-built formulations to reach even a few percent.
Sprays have become one of the most visible formats in the peptide market, and the pitch is consistent: the product bypasses digestion, absorbs rapidly under the tongue, and delivers results comparable to injection. Each of those statements is a pharmacokinetic claim, meaning a claim about how much intact peptide reaches the bloodstream and how fast. Pharmacokinetic claims can be tested, and the test is not complicated: give the product, sample blood, measure the peptide.
The argument of this post is that oral spray claims fail at three separate points before that test is even run, that the approved drugs most often cited in their defence show how hard the problem actually is, and that the measurement which would settle the question is, for the peptides most commonly sold as sprays, missing from the published record. The point is not that every spray is fraudulent. It is that an unmeasured claim is not evidence, however confidently it is stated.
The Claim Being Sold, and What It Would Require
Spray marketing typically rests on three assertions. Each one implies a specific measurable result.
| Marketing assertion | What it would require to be true | What would demonstrate it |
|---|---|---|
| “Bypasses digestion” | Most of the dose crosses the oral mucosa before it is swallowed | Plasma levels of intact peptide after spraying, compared with the same dose swallowed |
| “Rapid sublingual absorption” | The peptide permeates the oral epithelium quickly and intact | Time to peak concentration and peak level, measured by a validated assay |
| “Comparable to injection” | Bioavailability approaches that of the injected route | Area under the curve versus an injected reference, with variability reported |
The right-hand column describes a standard pharmacokinetic study. It is the same evidence regulators required for every approved non-injectable peptide discussed below. A spray making any of the assertions in the left-hand column without citing that study has stated a hypothesis about a route, not a finding about a product.
The pattern is easy to find. Comparison content for one widely sold research peptide quotes systemic bioavailability ranges for enhanced sublingual sprays while acknowledging, in the same article, that no peer-reviewed human bioavailability data for that peptide exists for any route. A figure without a source is not a measurement.
Failure Point 1: The Mouth Does Not Hold the Dose
A sprayed liquid has to stay in contact with the mucosa long enough to cross it. The mouth is built to prevent exactly that.
A 2025 review of oral cavity peptide delivery (Biomedicines) names rapid salivary clearance as one of the three principal barriers, alongside the epithelium itself and the enzymes in saliva. A liquid spread over the cheeks and palate has no retention mechanism unless the formulation supplies one, and whatever saliva carries away is swallowed.
Once swallowed, the spray is an oral solution. It faces gastric acid, pepsin, pancreatic proteases, and brush-border peptidases, the barriers that Tuvia and colleagues (Pharmaceutical Research, 2014) describe as limiting passive intestinal absorption of any hydrophilic peptide longer than about three amino acids. “Bypasses digestion” holds only for the fraction that never reaches the stomach, and no spray marketing we have seen quantifies that fraction.
Failure Point 2: The Lining Does Not Let Peptides Through
The fraction that does stay in contact meets a barrier. A review of buccal peptide delivery (Şenel and colleagues) describes peptide transport across oral mucosa as passive diffusion, mainly between cells, through an organized lipid layer in the upper epithelium that acts as the main permeability barrier. The same review concludes that plain solutions have limited usefulness for peptide delivery and that absorption promoters would be essential.
Three further details make an oral spray the least favourable version of this route.
Buccal tissue is the weaker site. A review of buccal delivery systems notes that buccal mucosa is less permeable than sublingual mucosa and offers a smaller absorptive area. Most sprays disperse across the cheeks and palate rather than staying under the tongue.
The mouth degrades peptides. The same review identifies aminopeptidase activity as the major enzymatic barrier to buccal peptide delivery in porcine tissue studies.
Size works against absorption. Mucosal absorption falls as molecular size rises. A review of nasal peptide delivery (Ozsoy and colleagues) puts typical nasal bioavailability for hydrophilic peptides and proteins below 1%, with absorption declining above roughly 1,000 Da. Most research peptides sold as sprays exceed that threshold. BPC-157, for example, is 1,419 Da.
Failure Point 3: The Peptide May Not Survive the Bottle
Absorption assumes the intended peptide is present, intact, at the stated concentration when the spray is actuated. A liquid format makes that the hardest assumption to satisfy.
Peptides are generally more stable as lyophilized solids than in solution, which is why research peptides ship as powders and why reconstituted material carries short storage windows, as set out in our peptide reconstitution and storage stability guide. A premixed spray holds the peptide in aqueous solution for its entire shelf life, at whatever temperature the bottle sees in transit and storage.
In solution, peptides degrade through deamidation, oxidation, and aggregation at rates governed by pH, buffer, temperature, and sequence. A survey of these pathways (Cleland and colleagues, 1993) concluded that their effect on biological activity has to be determined case by case. A certificate issued for raw peptide before formulation describes neither the finished liquid nor the liquid after weeks on a shelf, a limitation covered in our guide to reading a peptide certificate of analysis.
What It Actually Took to Get Peptides Across a Mucosa
The strongest defence of oral spray claims is that non-injectable peptides exist. They do. Their development records are the clearest evidence of how far a plain spray falls short.
| Approved product | Route | What made absorption possible | Measured bioavailability |
|---|---|---|---|
| Oral semaglutide tablet | Swallowed, absorbed in stomach | SNAC absorption enhancer; molecule engineered against DPP-4 degradation | ~0.4–2% (FDA label) |
| Oral octreotide capsule | Swallowed, absorbed in intestine | Enteric coating; medium-chain fatty acid permeation enhancer | ~0.25% (UCD repository) |
| Desmopressin tablet | Swallowed | Very high potency | ~0.16% of IV (US label) |
| Desmopressin lyophilisate | Sublingual | Freeze-dried matrix held under the tongue | ~0.25% (UK SmPC) |
| Desmopressin nasal spray | Nasal | Small molecule (1,183 Da); very high potency | 3.3–4.1% (label record) |
Three patterns run through every row.
Each needed engineering specific to the molecule. Buckley and colleagues (Science Translational Medicine, 2018) showed that oral semaglutide absorption occurs in a zone close to the eroding tablet, requires the SNAC enhancer, and is compound-specific. The molecule itself carries a fatty di-acid side chain for albumin binding, the half-life logic covered in our discussion of albumin-binding half-life extension.
Each reached a fraction of a percent to a few percent. These drugs work because they are extremely potent. A small fraction of the dose is enough. That is not true of every peptide.
The one liquid tested sublingually failed. A 1993 pharmacokinetic study of desmopressin (Fjellestad-Paulsen and colleagues, Clinical Endocrinology) compared several routes, and later patent literature describing that study reports that the liquid nasal formulation, given sublingually, produced no detectable desmopressin in blood. The sublingual product that eventually reached approval was a solid freeze-dried matrix.
The Missing Measurement
For the peptides most heavily marketed as sprays, the study that would support an absorption claim has not been published.
BPC-157 illustrates the gap. The first systematic pharmacokinetic study of the peptide (He and colleagues, Frontiers in Pharmacology, 2022) tested only intravenous and intramuscular injection, in rats and beagle dogs. It reported an elimination half-life under 30 minutes, rapid breakdown into small fragments within about 10 minutes of dosing, and absolute bioavailability after intramuscular injection of roughly 14–19% in rats and 45–51% in dogs. No oral, sublingual, or spray route was studied.
That result cuts hard against spray marketing. Even a needle placed directly into muscle delivered well under complete exposure in one species. A spray has to clear every barrier an injection avoids. A phase I trial of an oral BPC-157 tablet with pharmacokinetic endpoints was registered in 2015 (NCT02637284); we were unable to locate published results.
Where a direct measurement is missing, spray claims tend to borrow evidence from elsewhere. None of it transfers.
- Injection data to spray. Results after injection describe what happens once the peptide is already circulating. They say nothing about whether a spray gets it there.
- One peptide to another. Semaglutide’s absorption was shown to be compound-specific. Its tablet data say nothing about an unrelated sequence.
- One formulation to another. Desmopressin ranged from undetectable to a few percent depending on dosage form. Same molecule, different results.
- Ingredient to product. Evidence for an ingredient validates the ingredient. Whether a given bottle delivers it intact depends on that bottle’s formulation, concentration, storage history, and actuation.
How to Test a Spray Claim Before Accepting It
Five questions separate a measured claim from an asserted one.
- Is there a pharmacokinetic study of this exact product? Intact peptide measured in plasma after administration of the finished spray, by a validated assay, against an injected reference.
- Does the cited evidence match the product? Same peptide and salt form, same route, comparable formulation. A study of a different molecule, a different route, or an injected form does not count.
- What is the formulation, and what is it for? A named absorption enhancer or retention system should come with evidence that it works for this peptide. A plain aqueous solution has to explain how it overcomes the barriers above.
- Is the finished liquid characterized? Identity and content testing on the formulated product, with stability data across the labelled shelf life. A raw-material certificate is not enough.
- Are the numbers sourced? Any bioavailability percentage should link to the study that measured it. Batch-tied analytical documentation is the baseline Peptide Wave applies to its own materials, set out in our batch verification standards.
A spray that fails the first question cannot pass the others in any way that matters for an absorption claim.
Frequently Asked Questions
Q1: Do peptide oral sprays actually work?
Direct Answer: For most research peptide sprays, nobody has published the measurement that would show whether the peptide reaches the bloodstream, so an absorption claim for those products is unsupported rather than proven or disproven.
- What the route allows: The oral mucosa can absorb some molecules directly, bypassing the gut and liver.
- What works against it: Salivary clearance, a lipid permeability barrier, oral peptidases, and the molecular size of most research peptides.
- What the approved record shows: Peptides approved for mucosal delivery used purpose-built dosage forms and reached fractions of a percent to a few percent.
Q2: Doesn’t a spray bypass the digestive system?
Direct Answer: Only the fraction that crosses the oral lining before being swallowed bypasses digestion, and that fraction is rarely, if ever, quantified for a peptide spray.
- Saliva: Liquid doses are cleared by saliva and swallowed, after which the peptide faces gastric acid and proteases.
- Retention: Approved sublingual peptides use solid dosage forms held in place, not free liquids.
- Evidence: A desmopressin liquid given sublingually was reported to produce no detectable blood levels.
Q3: If oral semaglutide works, why wouldn’t a peptide spray?
Direct Answer: Oral semaglutide shows that one engineered peptide can be absorbed from one engineered tablet. Its investigators described the absorption mechanism as compound-specific, so it says nothing about other peptides or formulations.
- Enhancer dependence: Absorption required co-formulation with SNAC.
- Molecular engineering: The peptide was modified for albumin binding and enzyme resistance.
- Magnitude: Even so, labelled bioavailability is roughly 0.4 to 2%.
Q4: Is there any absorption data for BPC-157 sprays?
Direct Answer: We found none. The only systematic pharmacokinetic study of BPC-157 tested intravenous and intramuscular injection in animals and did not study oral, sublingual, or spray administration.
- Half-life: Under 30 minutes after injection in rats and dogs.
- Injection bioavailability: About 14–19% intramuscular in rats and 45–51% in dogs.
- Size: At 1,419 Da, BPC-157 sits above the molecular weight where mucosal absorption typically falls.
Q5: Does a certificate of analysis prove a spray is absorbed?
Direct Answer: No. A certificate describes the composition of a sample at the time it was tested and says nothing about absorption, which can only be shown by measuring the peptide in blood after administration.
- Timing: A certificate for raw peptide does not describe a formulated liquid after storage.
- Scope: Chromatographic purity does not report degradation in solution or excipient effects.
- What would be needed: Finished-product testing plus a pharmacokinetic study by the intended route.
Q6: Are nasal peptide sprays any different?
Direct Answer: Nasal delivery has a stronger approved-drug record for small, very potent peptides, but bioavailability remains low and falls with molecular size, so the same evidence standard applies.
- Approved example: A desmopressin nasal spray label reports 3.3 to 4.1% bioavailability.
- Barriers: Mucociliary clearance moves deposited material to the throat, and nasal peptidases degrade peptides in place.
- Typical range: Reviews put nasal bioavailability for hydrophilic peptides below 1%.
What a Spray Would Have to Show
The published record supports a specific conclusion about peptide oral sprays. The route faces salivary clearance, a lipid barrier, oral enzymes, and size limits; the liquid format puts the peptide’s stability at risk for its whole shelf life; and the approved products that succeeded on mucosal routes did so with molecule-specific engineering and still reached only low single-digit bioavailability.
Against that background, a spray marketed as bypassing digestion or matching injection is making a claim that would be remarkable if true, and remarkable claims carry a proportionate burden. The burden is a single, well-defined study: the finished product, given by its intended route, with intact peptide measured in plasma against an injected reference. Until a product publishes that study, its absorption claim is marketing, not evidence.
This article is provided for scientific reference in preclinical and in vitro research contexts. It does not describe or recommend any use in humans or animals. Compounds discussed are not approved by Health Canada for any therapeutic indication.
All Peptide Wave products are intended strictly for laboratory research use only. Not approved for, nor intended for, human or veterinary consumption.
Ready to Advance Your Research?
Browse our catalog of verified research peptides, sourced and shipped exclusively within Canada. COAs available on request.
Disclaimer: All Peptide Wave products are intended strictly for laboratory research use only. Not approved for, nor intended for, human or veterinary consumption.
